ACTRIMS Investor Call
Sanofi was pleased to invite investors and analysts to participate in a live webcast discussing tolebrutinib data presented during the ACTRIMS scientific program (February 24-26,2022).
(16h00 CET / 10:00am EST)
Avec
![Dietmar Berger](/optim/dotcom/content-app/events/investor-presentation/2022/ACTRIMS-Investor-Call-2022/dietmar-01_20230405202911.png?size=small)
Dietmar Berger
Global Head of Development,
![Tom Snow](/optim/dotcom/content-app/events/investor-presentation/2022/ACTRIMS-Investor-Call-2022/tom-02_20230405202911.png?size=small)
Tom Snow
Global Franchise Head, Neurology
![Erik Wallstroem](/optim/dotcom/content-app/events/investor-presentation/2022/ACTRIMS-Investor-Call-2022/erik-03_20230405202911.png?size=small)
Erik Wallstroem
Therapeutic Area Head, Multiple Sclerosis
![Anthony Traboulsee](/optim/dotcom/content-app/events/investor-presentation/2022/ACTRIMS-Investor-Call-2022/anthony-04_20230405202911.png?size=small)
Anthony Traboulsee
Professor and Research Chair of the MS Society of Canada at the University of British Columbia,Vancouver
![Tim Turner](/optim/dotcom/content-app/events/investor-presentation/2022/ACTRIMS-Investor-Call-2022/tim-05_20230405202911.png?size=small)
Tim Turner
Global Project Head, Neurology